LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients

Abstract

RPL554 is a novel, well tolerated dual PDE3/4 inhibitor with significant bronchodilator activity in COPD & asthma together with anti-inflammatory properties. We evaluated the bronchodilator effect of RPL554 administered on top of salbutamol (SAL) or ipratropium (IPR) in COPD patients. In this randomised, double-blind, double-dummy, placebo (PBO)-controlled, 6 way crossover study moderate-severe COPD subjects received SAL (200μg), IPR (40μg) or PBO pMDI followed by nebulised RPL554 (6mg) or PBO. 30 subjects completed. Spirometry & body plethysmography were conducted pre-dose & up to 12h post dose. RPL554 produced significant (>60%) & clinically meaningful additive bronchodilation when dosed with either SAL or IPR (p 2 agonist or an anti-cholinergic due to it9s novel mechanism of action. RPL554 is a promising treatment for COPD & combines significant bronchodilator effects with anti-inflammatory properties.